clinical trial · NCT05826015

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Washington University School of Medicine →·phase1·withdrawn

Recurrent High Grade Uterine CancerPaclitaxelBatiraxcept

brief summary

The purpose of this study is to determine safety and tolerability of AVB-500 when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer.

started

Oct 31, 2024

primary completion

Jun 3, 2029

completion

Jun 4, 2034

last updated

Oct 2, 2024

official title

Phase I/IB of AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol